DOCSLIB.ORG

COVIPENDIUM Aug4.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
COVIPENDIUM Aug4.Pdf COVIPENDIUM Information available to support the development of medical countermeasures and interventions against COVID-19 Cite as: Martine DENIS, Valerie VANDEWEERD, Rein VERBEEKE, Anne LAUDISOIT, Tristan REID, Emma HOBBS, Laure WYNANTS & Diane VAN DER VLIET. (2020). COVIPENDIUM: information available to support the development of medical countermeasures and interventions against COVID-19 (Version 2020-08-04). Transdisciplinary Insights. This document is conceived as a living document, updated on a weekly basis. You can find its latest version at: https://rega.kuleuven.be/if/corona_covid-19. The COVIPENDIUM is based on open-access publications (scientific journals and preprint databases, communications by WHO and OIE, health authorities and companies) in English language. Please note that the present version has not been submitted to any peer-review process. Any comment / addition that can help improve the contents of this review will be most welcome. For navigation through the various sections, please click on the headings of the table of contents and follow the links marked in blue in the document. Authors: Martine Denis, Valerie Vandeweerd, Rein Verbeke, Anne Laudisoit, Tristan Reid, Emma Hobbs, Laure Wynants, Diane Van der Vliet COVIPENDIUM version: 04 AUG 2020 Transdisciplinary Insights - Living Paper | 1 Contents List of abbreviations .......................................................................................................................................................... 9 Introduction .................................................................................................................................................................... 10 The virus .......................................................................................................................................................................... 10 Coronaviruses ............................................................................................................................................................. 10 SARS-CoV-2 is a betacoronavirus ................................................................................................................................ 11 Genome structure ....................................................................................................................................................... 12 Origin of the virus ....................................................................................................................................................... 13 Multiple reasons to rule out a laboratory origin .................................................................................................... 15 Sequence diversity among isolates ............................................................................................................................. 16 Sequence homology of the S gene .............................................................................................................................. 18 Structure of S and interactions with the ACE2 receptor ............................................................................................. 18 Other SARS-CoV-2 genes and proteins ....................................................................................................................... 20 Immunity to SARS-CoV-2 infection ................................................................................................................................. 20 Epitope predictions ..................................................................................................................................................... 20 Observations in COVID-19 patients ............................................................................................................................ 21 Comparisons between symptomatic and asymptomatic subjects ......................................................................... 21 Antibody response .................................................................................................................................................. 22 Cellular responses ................................................................................................................................................... 24 Immunity to other coronaviruses and cross-reactivity ............................................................................................... 26 Cross-reactivity of antibodies ................................................................................................................................. 26 Immune evasion mechanisms ..................................................................................................................................... 27 RNAi ......................................................................................................................................................................... 27 Clinical disease ................................................................................................................................................................ 27 Initial observations in Wuhan ..................................................................................................................................... 27 Incubation period ........................................................................................................................................................ 27 Description of clinical disease ..................................................................................................................................... 28 Clinical disease in China .......................................................................................................................................... 28 Clinical disease outside China ................................................................................................................................. 31 Non-respiratory symptoms ..................................................................................................................................... 31 Clinical imaging ........................................................................................................................................................... 34 Chest computed tomography ................................................................................................................................. 34 Lung ultrasound ...................................................................................................................................................... 36 Authors: Martine Denis, Valerie Vandeweerd, Rein Verbeke, Anne Laudisoit, Tristan Reid, Emma Hobbs, Laure Wynants, Diane Van der Vliet COVIPENDIUM version: 04 AUG 2020 Transdisciplinary Insights - Living Paper | 2 Laboratory finding & biomarkers ................................................................................................................................ 37 Virus load ................................................................................................................................................................ 37 Cell counts ............................................................................................................................................................... 38 Biochemistry ........................................................................................................................................................... 40 Coagulation parameters.......................................................................................................................................... 41 Time from illness onset to death ................................................................................................................................ 41 Case fatality rate ......................................................................................................................................................... 42 Case fatality rate in China ....................................................................................................................................... 42 Case fatality rate outside China .............................................................................................................................. 43 Special populations ..................................................................................................................................................... 45 Elderly ..................................................................................................................................................................... 45 Haemodialysis patients ........................................................................................................................................... 45 Cancer patients ....................................................................................................................................................... 45 Immunocompromised patients .............................................................................................................................. 45 Primary Antibody Deficiencies patients .................................................................................................................. 45 Children ................................................................................................................................................................... 45 Pregnancy
Load more

Recommended publications
  • The Epidemiology of COVID-19 in Canada in 2020: the Pre-Vaccine Era February 2021
    The Epidemiology of COVID-19 in Canada in 2020: The Pre-Vaccine Era February 2021 An RSC Policy Briefing The Epidemiology of COVID-19 in Canada in 2020: The Pre-Vaccine Era An RSC Policy Briefing Authors Wendy Sligl (Chair) University of Alberta David Waldner University of Alberta Jennie Johnstone University of Toronto Robyn Harrison University of Alberta Duncan Webster Dalhousie University Lynora Saxinger University of Alberta Peer Review Monitor Tom Marrie, FRSC Dalhousie University Peer Reviewers Nick Daneman University of Toronto Rob Fowler University of Toronto Srinivas Murthy The University of British Columbia David Patrick The University of British Columbia Dan Reid Dalhousie University Robert Strang Chief Medical Officer of Health, Nova Scotia Suggested citation for Policy Briefing Report: Waldner D, Harrison R, Johnstone J, Saxinger L, Webster D, Sligl W. The Epidemiology of COVID-19 in Canada in 2020: The Pre-Vaccine Era. Royal Society of Canada. 2021 Cover Art Christine De Vuono, For Your Own Good, (2020) Over the course of the pandemic, those in long term care facilities have been hit hardest with the impact of COVID-19 outbreaks. The response has been to lock down care homes and ban visitors, volunteers and even care packages, as attempts to stop the virus from entering the facility. This had the unintended, but very real consequence of isolating our most vulnerable from those who care for and love them. “For Your Own Good”, made of 100 carved figures from identical bars of soap, then placed in mason jars, which in turn are placed on shelves, allow us to look in on the miniature elderly figures, who look out at us.
    [Show full text]
  • An Update Review of Globally Reported SARS-Cov-2 Vaccines in Preclinical and Clinical Stages
    International Immunopharmacology 96 (2021) 107763 Contents lists available at ScienceDirect International Immunopharmacology journal homepage: www.elsevier.com/locate/intimp Review An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages Hamid Motamedi a, Marzie Mahdizade Ari b, Shirin Dashtbin b, Matin Fathollahi a, Hadi Hossainpour a, Amirhoushang Alvandi a,c, Jale Moradi a, Ramin Abiri a,d,* a Department of Microbiology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran b Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran c Medical Technology Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran d Fertility and Infertility Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran ARTICLE INFO ABSTRACT Keywords: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the rapidly spreading COVID-19 pandemic COVID-19 in the world. As an effective therapeutic strategy is not introduced yet and the rapid genetic SARS-CoV-2 variations in the virus, there is an emerging necessity to design, evaluate and apply effective new vaccines. An Vaccines acceptable vaccine must elicit both humoral and cellular immune responses, must have the least side effects and the storage and transport systems should be available and affordable for all countries. These vaccines can be classified into different types: inactivated vaccines, live-attenuated virus vaccines, subunit vaccines, virus-like particles (VLPs), nucleic acid-based vaccines (DNA and RNA) and recombinant vector-based vaccines (repli­ cating and non-replicating viral vector). According to the latest update of the WHO report on April 2nd, 2021, at least 85 vaccine candidates were being studied in clinical trial phases and 184 candidate vaccines were being evaluated in pre-clinical stages.
    [Show full text]
  • Kyle Wilfer UM Advisor: Dr. Mary Shariff (Associate Dean J.D. Program) Robson Hall Faculty of Law, University of Manitoba
    Amending the Canada Health Act to Improve Canada’s Rapidly Changing Long-Term Care Sector Kyle Wilfer UM Advisor: Dr. Mary Shariff (Associate Dean J.D. Program) Robson Hall Faculty of Law, University of Manitoba Motivation, Relevance and Goal of Research Analysis/Findings A. Defining Long-Term Care, Impact Relevance to Canadians This research conducts a preliminary analysis to better understand whether an Long-Term Care: Care that provides both medical and personal support to individuals E. COVID in LTC and the CAF “Operation Laser” Findings amendment to Canada Health Act (CHA) would improve Long-Term Care (LTC) in who are no longer able to live in their own homes or within the community. Commonly Canada. • 80% of all COVID deaths in Canada were reported in LTCFs and retirement referred to as nursing homes, they provide round-the-clock medical and social support homes for those with more complex health care needs. • The provincial/federal response to COVID in LTC: restrict outside visitors of This research was prompted by the current COVID-19 virus pandemic which is affecting • There are approximately 1360 LTCFs across Canada (excluding Quebec). LTC residents, limit movement of LTC staff between LTCFs, increase the millions of Canadians. In particular, the pandemic has shed light on the troubling situation in • It is predicted that there will be a need for an additional 199,000 LTC beds by 2035, certain Canadian Long-Term Care facilities (LTCFs) as investigated by the Canadian Armed translating to $194 billion in capital spending and operation costs. amount of personal protective equipment (PPE), isolation of residents of Forced Military, Operation Laser (CAF reports).
    [Show full text]
  • Pandemic.Pdf.Pdf
    1 PANDEMICS: Past, Present, Future Published in 2021 by the Mahatma Gandhi Institute of Education for Peace and Challenges & Opportunities Sustainable Development, 35 Ferozshah Road, New Delhi 110001, India © UNESCO MGIEP This publication is available in Open Access under the Attribution-ShareAlike Coordinating Lead Authors: 3.0 IGO (CC-BY-SA 3.0 IGO) license (http://creativecommons.org/licenses/ ANANTHA KUMAR DURAIAPPAH by-sa/3.0/ igo/). By using the content of this publication, the users accept to be Director, UNESCO MGIEP bound by the terms of use of the UNESCO Open Access Repository (http:// www.unesco.org/openaccess/terms-use-ccbysa-en). KRITI SINGH Research Officer, UNESCO MGIEP The designations employed and the presentation of material throughout this publication do not imply the expression of any opinion whatsoever on the part of UNESCO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. The ideas and opinions expressed in this publication are those of the authors; they Lead Authors: NANDINI CHATTERJEE SINGH are not necessarily those of UNESCO and do not commit the Organization. Senior Programme Officer, UNESCO MGIEP The publication can be cited as: Duraiappah, A. K., Singh, K., Mochizuki, Y. YOKO MOCHIZUKI (Eds.) (2021). Pandemics: Past, Present and Future Challenges and Opportunities. Head of Policy, UNESCO MGIEP New Delhi. UNESCO MGIEP. SHAHID JAMEEL Coordinating Lead Authors: Director, Trivedi School of Biosciences, Ashoka University Anantha Kumar Duraiappah, Director, UNESCO MGIEP Kriti Singh, Research Officer, UNESCO MGIEP Lead Authors: Nandini Chatterjee Singh, Senior Programme Officer, UNESCO MGIEP Contributing Authors: CHARLES PERRINGS Yoko Mochizuki, Head of Policy, UNESCO MGIEP Global Institute of Sustainability, Arizona State University Shahid Jameel, Director, Trivedi School of Biosciences, Ashoka University W.
    [Show full text]
  • A Perfect Storm?
    DND photo BN2012-0408-02 by Corporal Pierre Habib Corporal Pierre by BN2012-0408-02 DND photo This Bagotville-based CF-18, which graphically displays cosmetic wear appropriate to its age, is rather symbolic of the overdue need for a fighter replacement decision. A Perfect Storm? by Martin Shadwick t would, at least at this juncture, be imprudent and recent British defence review, although calling for additional premature to suggest that the eye-watering levels of and substantial personnel reductions in the British Army, was public spending associated directly or indirectly with noticeably more charitable toward the Royal Navy (and to a the pandemic will inevitably trigger significant cuts in lesser extent the Royal Air Force). Indeed, it could be argued Canadian defence spending—with all that implies in that the cuts in the British Army’s end strength and holdings of Iterms of military capabilities and force structure—and the de older equipment were necessary to help generate funding in the facto evisceration of the now four-year-old defence policy statement, Strong, Secure, Engaged. Indeed, there have been suggestions in some quarters that height- ened or at least accelerated defence spending, most likely in terms of shovel- ready infrastructure, could prove useful as an economic stimulant. Other observers have acknowledged that more than a few nation-states have paused or scaled back at least some projected defence procurement, but are quick to note that others—Australia and Sweden spring readily to mind—are still moving forward with ambitious defence modernization and expansion schemes. Even the Systems. BAE A recent concept design for the proposed Canadian Surface Combatant.
    [Show full text]
  • Iran Hopes to Defeat COVID with Home-Grown Crop of Vaccines
    Q&A Iran hopes to defeat COVID with home-grown crop of vaccines Iran is one of few Middle Eastern nations to transfer money is restricted, it is difficult with the capacity to develop vaccines. It to buy drugs and medicines. And we have has been doing so in earnest: more than the technology to produce vaccines, so why ten are in development, but little is known not use it? To ensure the safety of Iranians, it about them outside Iran. Nature speaks makes sense to develop a variety of vaccines to Kayhan Azadmanesh, head of the using different research and development virology division at the Pasteur Institute of strategies, as China has done. Iran in Tehran, about the nation’s vaccine landscape. Azadmanesh also advises the Why are Iranian researchers reluctant to Iranian government and is developing publicize their work internationally? vaccines through his spin-off company This could be another effect of the sanctions. Humimmune Biotech. Researchers in Iran might not want to draw too much attention to their work in case they How badly has the pandemic affected Iran? put potential partnerships in jeopardy or they Since January 2020, we’ve had five waves. run the risk of losing access to raw materials. We’re currently experiencing the highest Researchers are also extremely busy number of new cases reported so far, with during the pandemic. But some have started MAJID ASGARIPOUR/WANA VIA REUTERS MAJID ASGARIPOUR/WANA around 40,000 a day, and the most common to share results. In June, the researchers variant we detect is Delta.
    [Show full text]
  • Accelerating Vaccination Against Covid-19
    Accelerating vaccination against Covid-19 Press release of the French National Academy of Medicine April 12, 2021 The major challenge in overcoming the current health crisis is to acquire a sufficient herd immunity to control the circulation of SARS-CoV-2 and to consider the relaxation of restriction measures. Two factors contribute to this collective immunity: the proportion of people who have been infected since the beginning of the pandemic, estimated at 20% of the French population, and the vaccination coverage, which has just exceeded 18% of adults for the first injection. Post-infectious immunity is based on neutralizing antibodies that persist for more than one year after a moderate or severe form of Covid-19, and 6 to 8 months after an asymptomatic form [1], but also on the cellular response of T lymphocytes. This observation has led the French High Authority for Health to recommend that vaccination of immunocompetent individuals with confirmed SARS-CoV-2 infection be delayed for 3 to 6 months after the infectious episode and reduced to a single dose [2]. The vaccination coverage rate to reach the control of the epidemic has been increased to take into account the increased transmissibility of the B.1.1.7 variant, known as "British", which has become predominant throughout metropolitan France. According to the Pasteur Institute's modelling, more than 90% of the adult population would need to be vaccinated to achieve this objective, as long as the vaccination of children is not foreseen [3]. These estimates reinforce the prospect of a sustained circulation of SARS-CoV-2, which may lead to the emergence of new variants, with deleterious consequences on public health and the country's economy.
    [Show full text]
  • What the COVID-19 Pandemic Means for Defence Funding
    Sustaining Strong, Secure and Engaged Funding: What the COVID-19 Pandemic Means for Defence Funding by James A. Clarke The risk of interstate conflict, including among great powers, is higher than at any time since the end of the Cold War. – Daniel R. Coats, Director of National Intelligence Introduction The Government has no higher obligation than the safety and security of Canadian people. Our new strategic vision for defence reaffirms this overarching priority of the Canadian Armed Forces: defending Canada and protecting Canadians. – Strong, Secure, Engaged: Canada’s Defence Policy (p. 60) OVID-19 has changed the world. Forever. In fact, a recent article on The Economist website very succinctly framed the long-term financial challenge: “…governments are writing millions of cheques to households and firms in order to Chelp them survive lockdowns. At the same time, with factories, shops and offices shut, tax revenues are collapsing. Long after the covid-19 wards have emptied, countries will be living with the consequences.”1 That article concludes by portending that for future governments “Making budgets add up looks as if it will be a defining challenge of the post-covid world – one that today’s politicians have not yet even started to confront.”2 Defence of Canada/National Government The post-COVID reality will likely be the defining challenge for Canada’s next government and, pending the duration and impact of the pandemic, governments beyond. As our govern- should remain central to any post-COVID economic recovery ments develop fiscal plans to restore the economy, they must action contemplated by government.
    [Show full text]
  • MRC Centre for Outbreak Analysis and Modelling
    Centre for Outbreak Analysis and Modelling MRC Centre for ANNUAL REPORT Outbreak Analysis and Modelling www.imperial.ac.uk/medicine/outbreaks 2012 The Centre specialises in quantitative epidemiology encompassing mathematical modelling, statistical analysis and evolutionary epidemiology, to aid the control and Director’s message treatment of infectious diseases. April 2013 sees the Centre renewed for a second 5-year Consortium (led by Tim Hallett) and the Vaccine Modelling term, after we received an unprecedented 10 out of 10 Initiative – are up for renewal. However, grants are only score from the MRC subcommittee, which assessed the one aspect of the relationship. As important are the close performance of the Centre over its first term. Just as the working relationships between staff in the Centre and the work of the Centre over that time has been very much a Foundation, which sees our research increasingly used to team effort, so was the success of the renewal. inform Foundation strategy and delivery. The last few months have seen us start to drive through Despite its title, the Centre’s mission rapidly evolved to our strategy for the next 5 years. A crucial aspect of this encompass delivering innovative epidemiological analysis is to boost capacity in key research areas. It is therefore not only of novel infectious disease outbreaks, but also of my pleasure to welcome new academic staff into the endemic diseases of major global health significance. Our Centre. Xavier Didelot joined us last year as a lecturer in work on polio, malaria and HIV reflects this. However, the pathogen genetics, and our expertise in evolutionary and last few months have highlighted the ongoing relevance of genetic research will be further boosted this year by the our original mission to enhance preparedness and response recruitment of at least one additional member of academic to emerging disease threats.
    [Show full text]
  • News in Focus FEI/NYT/REDUX/EYEVINE SLAM YIK ​ Paramedics Transport a Man Thought to Be the First Person in Hong Kong to Have Contracted the New Coronavirus
    The world this week News in focus FEI/NYT/REDUX/EYEVINE SLAM YIK Paramedics transport a man thought to be the first person in Hong Kong to have contracted the new coronavirus. WHAT SCIENTISTS WANT TO KNOW ABOUT THE CORONAVIRUS OUTBREAK Researchers have sequenced the deadly pathogen’s genome — and are now rushing to find out how it spreads and how deadly it is. By Ewen Callaway and David Cyranoski Researchers fear similarities to the 2002–03 international concern — the agency’s highest epidemic of severe acute respiratory syn- level of alarm — after a meeting of officials last he world is racing to learn more about drome (SARS), which emerged in southern week, but that could change. the outbreak of a new viral infection that China and killed 774 people in 37 countries. Nature rounds up the questions at the heart was first detected in Wuhan, China, last Both are members of a large virus family, called of scientists’ efforts to understand the virus. month and is causing increasing alarm coronaviruses, that also includes viruses around the world. responsible for the common cold. How does the virus spread? TAs Nature went to press, officials in China China has taken unprecedented action to try This is the most urgent question surrounding had confirmed more than 4,500 cases of the to halt the outbreak — including putting Wuhan the outbreak. Chinese authorities have con- virus, which causes a respiratory illness, and and nearby cities on ‘lockdown’, restricting firmed that it spreads from person to person some 100 deaths. Around 50 cases had also travel in and out of the cities.
    [Show full text]
  • Special Edition - 5Th UPDATE 05/03/21
    IMMUNOWATCH Special edition - 5Th UPDATE 05/03/21 COVID-19 INTRODUCTION MabDesign and the COVID-19 pandemic The COVID-19 pandemic was matched by an unprecedented mobilisation of the French immunotherapy network and the pharmaceutical industry at large. Indeed, at the time of publication, three French companies already have preventive and/or therapeutic candidates currently undergoing Phase III clinical trials. In parallel, several bioprocessing sites across France have secured contracts for the production of both drugs and vaccines against SARS-CoV-2. These tremendous results were made possible through accelerated R&D as well as production and distribution logistics combined with facilitated access to information, resources and potential collaborators. MabDesign has been continuously adapting its actions and services to further support and enhance this nationwide pandemic response. Our latest and ongoing contribution to the fight against COVID-19 is through this special edition of Immunowatch and its regular updates. MabDesign’s Immunowatch is a one-of-a-kind information monitoring newsletter in the field of biomedicaments which aims at providing members of our association with the most recent and relevant data gathered or generated through the key expertise of MabDesign and its collaborators in scientific research, business intelligence, market analysis and intellectual property. Its original format has been modified to cater for the fast evolution of the response to the COVID-19 pandemic and allow rapid and pertinent updates. Immunowatch is done in collaboration with the MAbMapping Unit of the Ambition Recherche & Développement (ARD) Biomédicaments 2020 Phase II programme, funded by the Centre Val de Loire region. 2 Table of content 4.
    [Show full text]
  • Vaccines to Prevent Sars-Cov-2 Infection
    CORONAVIRUS DISEASE 2019 (COVID- 19):VACCINES TO PREVENT SARS-COV-2 INFECTION Dr Amitis Ramezani Head of Clinical Research group., Pasteur Institute of Iran Overview of vaccine development • Vaccines to prevent SARS-CoV-2 infection are considered the most promising approach for curbing the pandemic and are being vigorously pursued. As of winter 2020, several vaccines have become available for use in different parts of the world, over 40 candidate vaccines were in human trials, and over 150 were in preclinical trials. • When most people in a community are vaccinated against a disease, the ability of the pathogen to spread is limited. This is called ‘herd’ or ‘indirect’ or ‘population’ immunity. • When many people have immunity, this also indirectly protects people who cannot be vaccinated, such as very young babies and those who have compromised immune systems. • As with the development of pharmaceuticals, vaccine development progresses through preclinical evaluation and three distinct clinical stages, phases I, II, and III . Traditionally, these steps occur sequentially, and each usually takes several years for completion. SARS-CoV-2 vaccine development has accelerated to an unprecedented pace, with each step occurring over several months. Nevertheless, safety criteria remain stringent. • In the United States, the Food and Drug Administration (FDA) must approve progression to each next step in human trials, from initiation of phase I trials through progression to phase III trials. Steps in vaccine development Actions taken to ensure a
    [Show full text]